Previous 10 | Next 10 |
Pieris Pharmaceuticals (PIRS) and Boston Pharmaceuticals have brokered a licensing agreement for the development of PRS-342, a 4-1BB/GPC3 preclinical immuno-oncology bispecific fusion protein.Under the terms of the deal, Pieris will receive an upfront payment of $10M and up to $353M in milest...
Pieris will receive $10 million upfront and be entitled to receive additional milestone payments and tiered royalties Boston Pharmaceuticals will be primarily responsible for development of the program, with both parties collaborating during the investigational new drug (IND)-enabling ...
Penny Stocks To Buy According To Analysts Whether you love penny stocks or hate them, you can’t argue with the fact that big money can be made. By definition, the term itself references stocks to buy for less than $5. So even the slightest 50 cent move from the highest-priced pen...
Additional, ongoing confirmed durable partial response and three additional patients with stable disease as best response at the highest dose cohort of cinrebafusp alfa Durable anti-tumor activity in heavily pre-treated patient population including "cold" and HER2-low expressing t...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Apri...
Pieris Pharmaceuticals, Inc (PIRS) Q4 2020 Earnings Conference Call March 30, 2021, 08:00 AM ET Company Participants Tom Bures - VP, Finance Steve Yoder - President and CEO Hitto Kaufmann - Chief Scientific Officer Shane Olwill - SVP and Head, Translational Science Conference Call Participant...
Pieris Pharmaceuticals (PIRS): FY GAAP EPS of -$0.68 in-line.Revenue of $29.32M (-36.6% Y/Y) misses by $0.85M.Shares +6% PM.Press Release For further details see: Pieris Pharmaceuticals EPS in-line, misses on revenue
Company To Host an Investor Conference Call on Tuesday, March 30, 2021 at 8:00 AM EDT Pieris achieves $13 million milestone from AstraZeneca for initiation of PRS-060/AZD1402 phase 2a study and AstraZeneca to purchase $10 million equity stake in Pieris common stock as part of an amende...
When it comes to penny stocks, you can’t count out volatility. Price plays a big role, and based on the definition of these stocks, even 50 cents can mean big shifts in position value. If you’re new to these cheap stocks, you may not know what I’m talking about. The d...
Pieris Pharmaceuticals (PIRS) soars 15% premarket after Seagen (SGEN) makes a strategic equity investment in the company as part of an ongoing collaboration between them.The companies have amended their existing immuno-oncology agreement around joint development and commercial right...
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
2024-07-27 03:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 75.8% to $0.0457 on volume of 1,196,767,473 shares NVIDIA Corporation (NVDA) fell 6.8% to $114.25 on volume of 316,196,296 shares Sangamo Therapeutics Inc. (SGMO) rose 39.5% to $0.56 on volume of 261...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...